Stromal and epithelial predominant Wilms tumours have an excellent outcome: The SIOP 93 01 experience
- 25 June 2010
- journal article
- clinical trial
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 55 (2), 233-238
- https://doi.org/10.1002/pbc.22496
Abstract
Background Wilms tumour (WT) has various subtypes that are correlated with prognosis and require distinct therapy. Stromal predominant (SpWT) and epithelial WT (EpWT) have previously been associated with a good outcome. The current analysis describes the outcome and (tumour) characteristics of all patients with SpWT, EpWT, including highly differentiated epithelial type (HDET), treated according to the International Society of Pediatric Oncology (SIOP) 93‐01 study. Procedure All children older than 6 months and below 18 years of age with localized or metastatic WT and intermediate risk (IR) histology or HDET treated with pre‐operative chemotherapy were included in the present analysis. Results A total of 1,389 eligible patients had IR or HDET histology: 1% HDET, 4% EpWT, 10% SpWT, and 85% other IR. For EpWT/HDET, 93% had stage I/IIN−, 5‐year EFS was 90.2% and overall survival of (OS) 98.4%, as compared to 84.0% and 92.5% in other IR histology (NS). Stage I EpWT/HDET had a significant better outcome than stage I of other IR. In SpWT 82% of cases had stage I/IIN−; 5‐year EFS was 94.3% and OS 99.2%, significantly better compared to other IR histology. All patients with stage I are alive (2/149 relapses); 3/52 stage IIN−, 2/21 stage IIN+/III, and 6/12 stage IV patients relapsed (1 deceased per stage group). Conclusions The good outcome for EpWT and SpWT generally is very good which may be related to low age and low stage in most cases. A reduction of treatment intensity and/or duration may be justified especially for low stage SpWT that has an EFS close to 100%. Pediatr Blood Cancer 2010;55:233–238. © 2010 Wiley–Liss, Inc.Keywords
This publication has 22 references indexed in Scilit:
- Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trialThe Lancet, 2004
- Results of the SIOP 93-01/GPOH Trial and Study for the Treatment of Patients with Unilateral Nonmetastatic Wilms TumorKlinische Padiatrie, 2004
- Older Age Is an Adverse Prognostic Factor in Stage I, Favorable Histology Wilms’ Tumor Treated With Vincristine Monochemotherapy: A Study by the United Kingdom Children’s Cancer Study Group, Wilm’s Tumor Working GroupJournal of Clinical Oncology, 2003
- Outcome of children with cystic partially differentiated nephroblastoma treated with or without chemotherapyJournal of Pediatric Surgery, 2003
- Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOHAnnals of Oncology, 2001
- Complete necrosis induced by preoperative chemotherapy in Wilms tumor as an indicator of low risk: Report of the International Society of Paediatric Oncology (SIOP) Nephroblastoma Trial and Study 9Medical and Pediatric Oncology, 2000
- Fetal rhabdomyomatous nephroblastoma: a tumour of good prognosis but resistant to chemotherapyEuropean Journal of Cancer, 1999
- Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group.Journal of Clinical Oncology, 1998
- Second Malignant Neoplasms in Surivors of Wilms' Tumor: A Report From the National Wilms' Tumor StudyJNCI Journal of the National Cancer Institute, 1988